JP2018508567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508567A5 JP2018508567A5 JP2017555423A JP2017555423A JP2018508567A5 JP 2018508567 A5 JP2018508567 A5 JP 2018508567A5 JP 2017555423 A JP2017555423 A JP 2017555423A JP 2017555423 A JP2017555423 A JP 2017555423A JP 2018508567 A5 JP2018508567 A5 JP 2018508567A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- composition
- sequence encoding
- nucleotide sequence
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 40
- 102000038129 antigens Human genes 0.000 claims 40
- 108091007172 antigens Proteins 0.000 claims 40
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 19
- 230000003612 virological Effects 0.000 claims 19
- 101710043956 CEACAM5 Proteins 0.000 claims 13
- 101710043948 CEACAM7 Proteins 0.000 claims 13
- 102100002896 PSG2 Human genes 0.000 claims 13
- 101700004495 PSG2 Proteins 0.000 claims 13
- 101700010580 FLO11 Proteins 0.000 claims 10
- 102100006037 MUC1 Human genes 0.000 claims 10
- 101700052761 MUC1 Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- -1 CD86 Proteins 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000000051 modifying Effects 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 101700015421 CD276 Proteins 0.000 claims 2
- 102100019456 CD276 Human genes 0.000 claims 2
- 102100016384 HAVCR2 Human genes 0.000 claims 2
- 101700086956 IFNG Proteins 0.000 claims 2
- 102100016020 IFNG Human genes 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100012810 KIR3DL1 Human genes 0.000 claims 2
- 102100019764 PDCD1 Human genes 0.000 claims 2
- 108060007796 SPATA2 Proteins 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 101700068327 VTCN1 Proteins 0.000 claims 2
- 102100014952 VTCN1 Human genes 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 101700064281 ATP1 Proteins 0.000 claims 1
- 102100009333 BTLA Human genes 0.000 claims 1
- 101700047069 BTLA Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100000188 CD244 Human genes 0.000 claims 1
- 101700000388 CD244 Proteins 0.000 claims 1
- 102100019459 CD27 Human genes 0.000 claims 1
- 101700056583 CD27 Proteins 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 101700033362 CD28 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100003729 CD40LG Human genes 0.000 claims 1
- 102100005830 CD70 Human genes 0.000 claims 1
- 101700017377 CD70 Proteins 0.000 claims 1
- 102100019451 CD80 Human genes 0.000 claims 1
- 101700080477 CD80 Proteins 0.000 claims 1
- 102100005310 CTLA4 Human genes 0.000 claims 1
- 101700054183 CTLA4 Proteins 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 101710042195 GAL9 Proteins 0.000 claims 1
- 108060003143 GEM Proteins 0.000 claims 1
- 101710004393 HAVCR2 Proteins 0.000 claims 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 1
- 241001135569 Human adenovirus 5 Species 0.000 claims 1
- 101710039212 ICOSLG Proteins 0.000 claims 1
- 102100014733 ICOSLG Human genes 0.000 claims 1
- 102100008614 IDO1 Human genes 0.000 claims 1
- 101710031171 IDO1 Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 101710038974 KIR3DL1 Proteins 0.000 claims 1
- 108060004270 LAG3 Proteins 0.000 claims 1
- 102100017213 LAG3 Human genes 0.000 claims 1
- 102100004651 LGALS9 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 101710011976 PDCD1LG2 Proteins 0.000 claims 1
- 102100007289 PDCD1LG2 Human genes 0.000 claims 1
- 101700046490 PDL2 Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 102100008790 TNFRSF14 Human genes 0.000 claims 1
- 102100013135 TNFRSF4 Human genes 0.000 claims 1
- 101710040448 TNFRSF4 Proteins 0.000 claims 1
- 102100011846 TNFSF4 Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100015314 VSIR Human genes 0.000 claims 1
- 101710036075 VSIR Proteins 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 101710031453 groL2 Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (20)
- (a)MUC1抗原をコードするヌクレオチド配列を含むウイルスベクター;
(b)ブラキュリ抗原をコードするヌクレオチド配列を含むウイルスベクター;および
(c)CEA抗原をコードするヌクレオチド配列を含むウイルスベクター
を含む組成物。 - 前記MUC1抗原がMUC1−C抗原であり、前記MUC1−C抗原のアミノ酸配列は、配列番号9またはその断片に対して少なくとも90%の配列同一性を有する、請求項1に記載の組成物。
- 前記ブラキュリ抗原をコードする前記ヌクレオチド配列が、配列番号8またはその断片に対して少なくとも90%の配列同一性を有する、請求項1に記載の組成物。
- 前記CEA抗原をコードする前記ヌクレオチド配列が、配列番号1またはその断片に対して少なくとも90%の配列同一性を有する、請求項1に記載の組成物。
- 前記MUC1抗原をコードする前記ヌクレオチド配列を含むウイルスベクター、前記ブラキュリ抗原をコードする前記ヌクレオチド配列を含むウイルスベクター、および前記CEA抗原をコードする前記ヌクレオチド配列を含むウイルスベクターが、組換え型複製欠損性アデノウイルス5型ベクターである、請求項1に記載の組成物。
- 前記MUC1抗原をコードする前記ヌクレオチド配列を含むウイルスベクター、前記ブラキュリ抗原をコードする前記ヌクレオチド配列を含むウイルスベクター、および前記CEA抗原をコードする前記ヌクレオチド配列を含むウイルスベクターが、E2b遺伝子領域、E1遺伝領域、E3遺伝子領域、E4遺伝子領域、またはそれらの任意の組み合わせにおける欠失を含む、請求項1に記載の組成物。
- 免疫経路チェックポイントモジュレーター、siRNA、アンチセンス、小分子、模倣物、リガンドの組換え型、受容体の組換え型、抗体、またはこれらの組み合わせを含む分子組成物をさらに含む、請求項1に記載の組成物。
- 前記免疫経路チェックポイントモジュレーターが、以下:PD1、PDL1、PDL2、CD28、CD80、CD86、CTLA4、B7RP1、ICOS、B7RPI、B7−H3、B7−H4、BTLA、HVEM、KIR、TCR、LAG3、CD137、CD137L、OX40、OX40L、CD27、CD70、CD40、CD40L、TIM3、GAL9、ADORA、CD276、VTCN1、IDO1、KIR3DL1、HAVCR2、VISTA、およびCD244からなる群より選択される内在性免疫経路チェックポイントタンパク質またはその断片を標的とする、請求項7に記載の組成物。
- 前記免疫経路チェックポイントモジュレーターが、PD1タンパク質を標的とする、請求項7に記載の組成物。
- 免疫原性成分をさらに含む、請求項1に記載の組成物であって、前記免疫原性成分は、IFN−γ、TNFα、IL−2、IL−8、IL−12、IL−18、IL−7、IL−3、IL−4、IL−5、IL−6、IL−9、IL−10、およびIL−13の群より選択されるサイトカインを含む、組成物。
- ウイルスベクターが、前記MUC1抗原、前記ブラキュリ抗原および前記CEA抗原からなる群から選択される少なくとも2つの抗原をコードする配列を含む、請求項1に記載の組成物。
- 前記CEA抗原のアミノ酸配列が、配列番号10を含む、請求項1に記載の組成物。
- 処置を必要とする被験体を処置するための組成物であって、
前記組成物は、MUC1抗原をコードするヌクレオチド配列を含むウイルスベクター、ブラキュリ抗原をコードするヌクレオチド配列を含むウイルスベクター、およびCEA抗原をコードするヌクレオチド配列を含むウイルスベクターを含み、前記組成物は、処置を必要とする前記被験体に投与されることを特徴とし、そして、
前記組成物は、前記MUC1抗原、前記ブラキュリ抗原、または前記CEA抗原、あるいは、前記MUC1抗原、前記ブラキュリ抗原、または前記CEA抗原を発現する細胞に対する免疫応答を誘導し、
処置を必要とする前記被験体はがんを有する、組成物。 - 前記組成物は、5×10 11 ウイルス粒子(VP)の前記MUC1抗原をコードするヌクレオチド配列を含む前記ウイルスベクター、少なくとも5×10 11 ウイルス粒子(VP)の前記ブラキュリ抗原をコードするヌクレオチド配列を含む前記ウイルスベクター、および少なくとも5×10 11 ウイルス粒子(VP)の前記CEA抗原をコードするヌクレオチド配列を含む前記ウイルスベクターを含む、請求項13に記載の組成物。
- 前記免疫応答が、基底の少なくとも2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、10倍、15倍、20倍、または25倍である、請求項13に記載の組成物。
- 前記免疫応答が、抗原特異的抗体応答として、抗原特異的細胞媒介性免疫(CMI)として、抗原特異的IFN−γ分泌として、抗原特異的IL−2分泌として、ELISpotアッセイによって、またはこれらの任意の組み合わせによって測定される、請求項13に記載の組成物。
- 前記投与が皮下投与を含む、請求項13に記載の組成物。
- 前記被験体が、結腸直腸腺癌、転移性結腸直腸がん、進行MUC1−C、ブラキュリ、もしくはCEA発現結腸直腸がん、乳がん、肺がん、膀胱がん、または膵がんを有する、請求項13に記載の組成物。
- 処置を必要とする前記被験体がヒトである、請求項13に記載の組成物。
- 前記MUC1抗原がMUC1−C抗原であり、前記MUC1−C抗原のアミノ酸配列は、配列番号9またはその断片に対して少なくとも90%の配列同一性を有し、前記ブラキュリ抗原をコードする前記ヌクレオチド配列が、配列番号8またはその断片に対して少なくとも90%の配列同一性を有し、前記CEA抗原をコードする前記ヌクレオチド配列が、配列番号1またはその断片に対して少なくとも90%の配列同一性を有し、前記CEA抗原のアミノ酸配列が、配列番号10を含む、請求項13に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101969P | 2015-01-09 | 2015-01-09 | |
US62/101,969 | 2015-01-09 | ||
US201562150236P | 2015-04-20 | 2015-04-20 | |
US62/150,236 | 2015-04-20 | ||
PCT/US2016/012496 WO2016112195A1 (en) | 2015-01-09 | 2016-01-07 | Methods and compositions for combination immunotherapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018508567A JP2018508567A (ja) | 2018-03-29 |
JP2018508567A5 true JP2018508567A5 (ja) | 2019-02-14 |
JP6647315B2 JP6647315B2 (ja) | 2020-02-14 |
Family
ID=56356431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555423A Active JP6647315B2 (ja) | 2015-01-09 | 2016-01-07 | 組み合わせ免疫療法のための方法および組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11352642B2 (ja) |
EP (1) | EP3242940B1 (ja) |
JP (1) | JP6647315B2 (ja) |
KR (1) | KR102193635B1 (ja) |
CN (2) | CN113456812A (ja) |
AU (1) | AU2016205215B2 (ja) |
CA (1) | CA2974237C (ja) |
IL (1) | IL253341B (ja) |
WO (1) | WO2016112195A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3539567A1 (en) | 2007-07-02 | 2019-09-18 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
AU2017272356A1 (en) * | 2016-06-03 | 2018-12-20 | Etubics Corporation | Compositions and methods for the treatment of human papillomavirus (HPV)-associated diseases |
WO2018014006A1 (en) * | 2016-07-15 | 2018-01-18 | Etubics Corporation | Compositions and methods for flavivirus vaccination |
WO2018014008A1 (en) * | 2016-07-15 | 2018-01-18 | Etubics Corporation | Compositions and methods for alphavirus vaccination |
US11422127B2 (en) | 2016-12-07 | 2022-08-23 | Albany Medical College | Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens |
CA3049445A1 (en) * | 2017-01-17 | 2018-10-11 | The University Of Chicago | Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment |
US11020467B2 (en) | 2017-05-26 | 2021-06-01 | Etubics Corporation | Combination immunotherapies comprising IL-15 superagonists |
CA3069363A1 (en) * | 2017-07-11 | 2019-01-17 | Pfizer Inc. | Immunogenic compositions comprising cea muc1 and tert |
CN111542595B (zh) | 2017-11-10 | 2023-05-09 | 北京卡替医疗技术有限公司 | 经修饰的免疫细胞及其用途 |
US20210046177A1 (en) * | 2018-01-26 | 2021-02-18 | Nantcell, Inc. | Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy |
US11573230B2 (en) | 2018-01-26 | 2023-02-07 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
MX2020010421A (es) * | 2018-04-04 | 2021-01-15 | Altimmune Inc | Combinaciones de composición de vacunas inductoras de células t y usos de las mismas. |
EP3897691A4 (en) * | 2018-12-21 | 2022-08-31 | The Regents of the University of California | IL-10 VACCINES AND THEIR USES |
US20230036911A1 (en) * | 2019-12-30 | 2023-02-02 | Greffex, Inc. | Culture systems for the efficient production of gene transfer vectors |
KR102371663B1 (ko) * | 2020-01-21 | 2022-03-04 | 코오롱생명과학 주식회사 | 아데노바이러스 벡터 |
CN116059339B (zh) * | 2021-11-04 | 2023-09-22 | 元本(珠海横琴)生物科技有限公司 | 一种治疗和预防癌症的药物和应用 |
CN117110607B (zh) * | 2023-09-16 | 2024-01-26 | 鲁东大学 | 一种检测副溶血性弧菌的组合物及其应用 |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US820079A (en) | 1903-07-15 | 1906-05-08 | Auto Manual Piano Action Company | Musical instrument. |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
DE69312487T2 (de) | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
KR20080009171A (ko) | 1997-08-13 | 2008-01-24 | 더 유에이비 리서치 파운데이션 | 유전자 벡터의 국소 적용에 의한 백신접종 |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
ES2217585T3 (es) | 1997-10-10 | 2004-11-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea). |
US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
EP1447414B1 (en) | 1997-10-10 | 2007-06-06 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Antagonist peptides of carcinoembryonic antigen (CEA) |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
CA2354024C (en) * | 1998-12-09 | 2009-12-22 | Jeffrey Schlom | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
US7009042B1 (en) | 1999-10-07 | 2006-03-07 | Corixa Corporation | Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins |
EP1964573B1 (en) | 1999-10-22 | 2014-11-26 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
US20030232399A1 (en) | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
WO2002008436A2 (en) * | 2000-07-20 | 2002-01-31 | Genstar Therapeutics Corporation | Mini-adenoviral vector system for vaccination |
US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
US20040091995A1 (en) | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
CN100335121C (zh) | 2001-07-20 | 2007-09-05 | 得克萨斯大学体系董事会 | 涉及hpv相关的癌前期的和癌的生长(包括cin)的方法和组合物 |
US8236776B2 (en) | 2002-04-09 | 2012-08-07 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
CN1658899B (zh) | 2002-04-09 | 2013-01-02 | 安万特巴斯德有限公司 | 经修饰的cea核酸及表达载体 |
AU2003304203A1 (en) | 2002-10-29 | 2005-01-04 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
CN104147597A (zh) | 2002-12-16 | 2014-11-19 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
KR20060003903A (ko) | 2003-05-05 | 2006-01-11 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. | 사람 암배아 항원을 암호화하는 합성 유전자 및 이의 용도 |
US8207314B2 (en) | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
CN101173282B (zh) | 2003-07-21 | 2011-04-06 | P.安杰莱蒂分子生物学研究所 | 编码人表皮生长因子2/neu抗原的合成基因及其用途 |
CA2544946A1 (en) * | 2003-11-24 | 2005-03-06 | Sidney Kimmel Cancer Center | Mucin antigen vaccine |
EP1720905A2 (en) | 2003-12-11 | 2006-11-15 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
EP1697399B1 (en) | 2003-12-12 | 2016-11-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
ATE449105T1 (de) * | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
US8188244B2 (en) | 2004-02-11 | 2012-05-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Carcinoembryonic antigen fusions and uses thereof |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
WO2006033672A2 (en) | 2004-04-28 | 2006-03-30 | The Trustees Of The University Of Pennsylvania | Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
JP2008501360A (ja) | 2004-06-11 | 2008-01-24 | カソリック ユニバーシティー インダストリー アカデミー コオペレーション ファウンデーション | CEA−特異的な細胞毒性T細胞を生成する組み換えアデノウイルスAdVCEAで形質導入された樹枝状細胞、及びこれを含むワクチン並びに薬剤学的組成物 |
WO2006044923A2 (en) | 2004-10-18 | 2006-04-27 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis c infection |
EP1906997A2 (en) | 2005-07-11 | 2008-04-09 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
WO2007070392A2 (en) | 2005-12-12 | 2007-06-21 | Canji, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
JP2009534331A (ja) | 2006-04-21 | 2009-09-24 | トランジェーヌ、ソシエテ、アノニム | Hpv‐18を主体とするパピローマウイルスワクチン |
EP3539567A1 (en) | 2007-07-02 | 2019-09-18 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
CN101765434B (zh) | 2007-07-27 | 2014-12-17 | 伊玛提克斯生物技术有限公司 | 抗肿瘤相关肽及相关抗癌疫苗组合物 |
CA2759013C (en) | 2009-04-17 | 2021-10-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy compositions against cancer and methods |
US20150182621A1 (en) | 2009-04-28 | 2015-07-02 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
EP2547792A4 (en) | 2010-03-14 | 2013-11-27 | Globeimmune Inc | PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY |
JP6096111B2 (ja) | 2010-05-10 | 2017-03-15 | アセンド・バイオファーマシューティカルズ・リミテッド | 免疫刺激組成物及びワクチン組成物 |
WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
RU2619850C2 (ru) | 2011-03-17 | 2017-05-18 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей с brachyury |
CA2844500C (en) | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
EP2809788B1 (en) | 2012-02-02 | 2019-09-04 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
EP3553086A1 (en) | 2012-05-31 | 2019-10-16 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
GB201214007D0 (en) | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
RU2014102939A (ru) | 2013-02-05 | 2015-08-10 | Нитто Денко Корпорейшн | Вакцинная композиция для чрескожного введения |
US10035832B2 (en) | 2013-10-23 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
WO2015104656A1 (en) * | 2014-01-07 | 2015-07-16 | Babita Agrawal | Immunomodulatory compositions and methods of use thereof |
WO2015123532A1 (en) | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
US10434152B2 (en) | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
EP3129036B1 (en) | 2014-04-11 | 2021-08-11 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
EP3673915A1 (en) | 2014-06-30 | 2020-07-01 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
EA037621B1 (ru) | 2015-03-23 | 2021-04-22 | Джаунс Терапьютикс, Инк. | Антитела к icos |
US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2016
- 2016-01-07 JP JP2017555423A patent/JP6647315B2/ja active Active
- 2016-01-07 EP EP16735415.8A patent/EP3242940B1/en active Active
- 2016-01-07 US US15/542,005 patent/US11352642B2/en active Active
- 2016-01-07 CN CN202110784166.7A patent/CN113456812A/zh active Pending
- 2016-01-07 CA CA2974237A patent/CA2974237C/en active Active
- 2016-01-07 CN CN201680014846.8A patent/CN107406857B/zh active Active
- 2016-01-07 AU AU2016205215A patent/AU2016205215B2/en active Active
- 2016-01-07 WO PCT/US2016/012496 patent/WO2016112195A1/en active Application Filing
- 2016-01-07 KR KR1020177022200A patent/KR102193635B1/ko active IP Right Grant
-
2017
- 2017-07-05 IL IL253341A patent/IL253341B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018508567A5 (ja) | ||
Tian et al. | Engineering strategies to enhance oncolytic viruses in cancer immunotherapy | |
Hollingsworth et al. | Turning the corner on therapeutic cancer vaccines | |
Evans et al. | Immune suppression and colorectal cancer | |
CN105331586B (zh) | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 | |
Dolcetti et al. | Immunotherapy for gastric cancer: time for a personalized approach? | |
Li et al. | Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself | |
Finn | Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic | |
Cui et al. | Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer | |
Heidegger et al. | RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade | |
JP2019521099A (ja) | Her2/neuを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法 | |
Sharma et al. | SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model | |
JP2018509163A5 (ja) | ||
JP2019508044A5 (ja) | ||
JP2018502922A5 (ja) | ||
WO2017100338A4 (en) | Improved compositions and methods for viral delivery of neoepitopes and uses thereof | |
JP2020517737A5 (ja) | ||
Cervera-Carrascon et al. | Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. | |
Zhao et al. | Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas | |
Basso et al. | T cell therapy for nasopharyngeal carcinoma | |
Han et al. | AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo | |
Turksma et al. | Immunotherapy for head and neck cancer patients: shifting the balance | |
Namkoong et al. | Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11 | |
Ahn et al. | A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model | |
Danishmalik et al. | Therapeutic tumor control of HER2 DNA vaccines is achieved by an alteration of tumor cells and tumor microenvironment by gemcitabine and anti-Gr-1 Ab treatment in a HER2-expressing tumor model |